www.drreddys.com Open in urlscan Pro
34.98.111.98  Public Scan

Form analysis
0 forms found in the DOM

Text Content

You need to enable JavaScript to run this app.
INVESTORSMEDIAPARTNERSCAREERSCONTACT US

HomeWho We AreOur BusinessesSustainabilityLife at Dr. Reddy’s
Home

Who We Are

Our Businesses

Sustainability

Life at Dr. Reddy's

HOME
About Us

Building A Sustainable Future

#WeAreDrReddys

Latest News

Who We Are

Purpose

Promises

Principles

Values

Leadership

Our Founder

Our Journey

Our Businesses

Our Business

Our Capabilities

Stories

Jobs

Contact Us

Sustainability

Milestones

Our ESG Goals

Reports and Disclosures

Community Initiatives

Employee Volunteering

People & Stories

Patient Stories

Patient Programmes

HCP Stories

Partner Stories

Be Our Partner

Life At Dr. Reddy's

Our culture

ASPIRE framework

Our People

Awards

Capability Building Programmes

Work With Us

Investors

Media

Business Partners

Job Seekers

Contact Us

Country Sites
Australia
Austria
Brazil
Canada
chile
china
colombia
france
germany
India
Italy
new zealand
romania
russia
south africa
spain
ukraine
united kingdom
united states
 * 
 * 
 * 
 * 
 * 
 * 
 * 
 * 

 * 
 * 
 * 
 * 
 * 
 * 
 * 
 * 
 * 
 * 



We are committed to providing access to affordable and innovative medicines,
driven by our purpose of ‘Good Health Can’t Wait’.

Our products and services are spread across our core businesses of Active
Pharmaceutical Ingredients (API), generics, branded generics, biosimilars and
over-the-counter pharmaceutical products around the world. We work towards
meeting unmet patients needs in the areas of gastro-enterology, cardiovascular,
diabetology, oncology, pain management and dermatology. We are investing in
businesses of the future including drug discovery, clinically-differentiated
assets and digital healthcare.


LEARN MORE


We started in 1984 with a modest investment and a bold vision.
Today, with research and development centres, manufacturing facilities and
commercial
presence across the globe, we serve over half a billion patients worldwide. We
aspire to
triple our reach and touch over 1.5 billion patients by 2030.

0
2
3
4
5
6
7
8
9
0
0
2
3
4
5
6
7
8
9
0
countries
0
2
3
4
5
6
7
8
9
0
0
2
3
4
5
6
7
8
9
0
nationalities
USD
0
2
3
4
5
6
7
8
9
0
.
0
2
3
4
5
6
7
8
9
0
0
2
3
4
5
6
7
8
9
0
bn
Revenue (As of FY '23)
0
2
3
4
5
6
7
8
9
0
0
2
3
4
5
6
7
8
9
0
.
0
2
3
4
5
6
7
8
9
0
%
EBITDA (As of FY '23)
~
0
2
3
4
5
6
7
8
9
0
0
2
3
4
5
6
7
8
9
0
,
0
2
3
4
5
6
7
8
9
0
0
2
3
4
5
6
7
8
9
0
0
2
3
4
5
6
7
8
9
0
employees


GOOD HEALTH CAN’T WAIT

Our purpose is to provide access to affordable and innovative medicines and
healthcare solutions. Read more about our purpose, principles and values.


WHO WE ARE



OUR CORE TENETS

Pioneering work based on science
Our deep science capabilities form the bedrock of our work enabling us to
innovate for patients. Our investment in complex chemistry and biology have led
us to several firsts. In India, we were among the first to export APIs at scale
and introduce many new molecules. We were the first in India to initiate novel
drug discovery in the 1990s and to receive 180-day exclusivity from the USFDA in
the 2000s. We focus on being first to market, helping us deliver on our
promises.
Progressive People Practices
We have pioneered practices such as ‘Self-Managed Teams’ in pharma. We develop
leaders through our initiatives such as our ‘New Horizons Leadership Programme’.
Our investment in people capabilities serves not just our company but also the
industry. We have set bold goals for ourselves in our diversity, equity and
inclusion journey. We aspire to create an environment in which people can
realise their full potential through work and continuous learning.
Rigour in Governance
We were the first Asian pharma company outside Japan to list on the New York
Stock Exchange in 2001. We are committed to the highest standards of compliance,
ethics and quality in every activity that we undertake. We are consistently
recognised by our stakeholders for our governance. We endeavour to set the bar
high and maintain the trust our stakeholders repose in us. We continue to work
on progressive and timely disclosures, transparent policies and processes.


OUR CURRENT ESG GOALS

Being committed to environmental stewardshipMaking our products accessible and
affordable to patientsContributing to a fairer and more socially inclusive
worldEnhancing trust with our stakeholders

--------------------------------------------------------------------------------

Reducing Carbon Emissions

 * 100% renewable power by 2030
 * Carbon neutrality in our direct operations (scope 1 and 2 emissions) by 2030
 * 12.5% reduction in indirect carbon emissions (Scope 3 emissions) by 2030

Water Positivity

 * Become water positive by 2025


LEARN MORE




#WEAREDRREDDYS

Welcoming our future leaders
Just the beginning of an exciting journey
Dr. Reddy’s family meets for a townhall
Launch of Womb to the World initiative
National Road Safety month
The finale of Celebration of Excellence
Spirit of Celebration of Excellence 2024
Overcoming complex scientific and regulatory barriers
Celebration of science – Minds in motion
Felicitation ceremony of our Chrysalis programme
We enter the UK consumer health market with our branded allergy medication
Histallay!
Vega Club wins Best Patient Support Programme
World Acidity Day
Unwavering patient centricity and execution excellence
Livelihood opportunities for youth
Adding more self-care women’s health products to our U.S. portfolio
Happy New Year 2024!
Ending 2023 with a happy, healthy 5k marathon
National Farmers Day
Christmas celebrations at our offices
Healthy gifting options at Celevida Wellness
Winner of the Supply Chain and Logistics Excellence Award
Our India business meets for a townhall
Dr. Reddy’s becomes the first pharma company to debut on the Dow Jones
Sustainability World Index
Winner of ‘Product of the Year 2023’ in Russia
High energy start to Celebrations of Excellence 2024
China International Import Expo (CIIE)
ET Employee Experience Awards
Diabetes awareness camps by our rural healthcare team
CII Industrial IP Awards 2023
DGN Congress 2023
Our first-ever alumni meet in North America
Great Place to Work - Myanmar
Announcing the roll-out of our wearable, Nerivio®, for migraine management
‘Manthan’ celebration by our R&D colleagues
Diwali celebrations
Great Place to Work – Malaysia
Quarterly global townhall
Halloween celebrations at our North America office
Recognised by Science Magazine for the second year in a row in its global top 20
pharma employers list
Breast Cancer Awareness Month
Our teams at CPhI Barcelona
Team Dr. Reddy’s Latin America wins Global Generics and Biosimilars Awards
Launch of direct-to-consumer e-commerce website ‘Celevida Wellness’ for diabetes
NJ Best Places to Work
Celebrations of Excellence 2024
Mid-autumn festival celebration by team China
Community Health Intervention Programme
#TensionMatLo… Pressure Check Kar Lo
On #WorldHeartDay, listen to Sunil Gavaskar!
Awarded the Technology Strategy Impact Award 2023 for APAC by Forrester
Margdarshak programme by our Women Safety Ambassadors
Dr. Reddy's ASPIRE - The Ultimate Case Study Challenge
Mintop shampoo recognised as Prestigious Rising Brand of India
Great Place to Work - China
Team Biologics observes silver jubilee
Birds and Beliefs by G V Prasad
Celevida recognised at the Prestigious Brands awards
Our India team wins three awards at the e4m Health and Wellness awards
Sustainable Raksha Bandhan celebrations in India
Launch of Sustainability Ambassador Programme in Mexic
Recognised by Financial Express and ECube Investment Advisors for our work in
sustainability
Dr. Reddy’s flag flying high at the NMDC Hyderabad Marathon
We have launched Saxagliptin and Metformin Hydrochloride Extended-Release
Tablets in the U.S.
Our India business team participates in a branding workshop
Dr. Reddy's family comes together for a townhall
Campus interaction with our leaders
Primary Healthcare Centre at Korlam, Srikakulam
Financial Planning Session by Women Safety Ambassadors
Official inauguration of our new office space in Myanmar
Our proposed rituximab biosimilar application has been accepted for review by
USFDA, EMA and MHRA
Presenting our first Integrated Annual Report
Junine Fiesta celebrations at our corporate office
Introducing Celehealth ImmunoPlus Kidz Gummies in India!
Little Free Library at our corporate office in Hyderabad
A gender sensitisation workshop by our Biologics team
Introducing ABLE - an Employee Resource Group of, by, and for colleagues with
disability
Launch of our trade generics business in India
Our Women Safety Ambassadors empowering women and creating awareness
Our colleagues participate in Green Marathon
Observing ’30 Days Of Pride’
Team Biologics meets for a townhall!
Participation of our China team in the 86th PharmChina exhibition
Glimpses of World Environment Day awareness activities
Building allies and enabling inclusion
Participation in the G20 summit
Successful completion of tocilizumab Phase I (IV route)
Our colleagues in North America observes Mental Health Awareness Month
Awareness session by our Community Health Intervention Programme on Menstrual
Hygiene Day
Vega Club, a patient support programme by Team Recura Alfa from our India
business
Winner in the ‘Learning Champion’ category at the LinkedIn Talent Awards India
2022
Welcoming our batch of engineering and management interns
The Financial Times (London) has named us an Asia – Pacific Climate Leader 2023!
Launch of Vivera as a dedicated business unit for nutrition in India
‘Stroll and Study’ event at our Bachupally campus
Team Brazil earns ‘Great Place to Work’ certification
Featured in the ‘Asia Book of Records’ for our initiative on World Hypertension
Day!
Our SHE&S team celebrates World Health Day
Dr. Reddy’s Laboratories announces the launch of Regadenoson Injection 0.4 mg/5
mL in the U.S. market
A person of many untold stories – watch our CEO Erez Israeli unplugged
Our Digital and Process Excellence (DPEx) team goes agile!
Our Risk Management Team wins the 'Masters of Risk - Healthcare and Pharma'
Award
Our legal team wins the Pharma and Healthcare Legal Team of the Year award
Emerging Markets Annual Meet
Rebalanz VITORS™ - Our partnership with Sonu Sood
Team API conducts our first K-Science Conference in Seoul
On-boarding our summer interns!
Safe motherhood initiatives by the Community Health Intervention Programme
Team Europe joins an interactive townhall
MPower 2023 – It’s time to #RiseUp and take charge!
Recognised one of ET's 'Best Organisations for Women 2023'
Interaction with our recruitment partners
India Rural Business teams won the ‘Excellence in Rural Health Initiative’ award
World Water Day celebrations by our Water Ambassadors!
My Health Index goes digital – with SVAAS Wellness Limited!
Congratulations to Team Thailand on earning the Great Place To Work
certification!
Celebrating the life and legacy of Dr. K. Anji Reddy!
Celebrating allyship!
Kick-starting National Safety Month in India!
Team Europe met for a townhall!
Meeting with leaders from Bill & Melinda Gates Foundation!
Adding women's health products to our U.S. portfolio
#TeamWorkIsDreamWork - A climb up the Rachakonda Fort!
Principal Industry Host at BioAsia 2023!
Two fantastic days of showcase in Algeria!
Team Biologics at Augsburg, Germany!
Launch of Fitness Scavenger Hunt 2.0 at our Biologics facility in Hyderabad
It’s a hat-trick! Our teams across geographies have earned three recognitions!
Digital Day by our R&D team in Hyderabad!
We have been included in Bloomberg Gender-Equality Index for the 6th year in a
row and S&P Global’s Sustainability Yearbook for the 3rd consecutive year
Bicycle distribution to school children by our R&D team
Our Road Safety Ambassadors continues to extend National Road Safety Week into a
month of awareness activities!
It's a double win for our India Business teams at the IHW Awards
We have launched Difluprednate Ophthalmic Emulsion 0.05% in the U.S. Market
We have won the Gold Shield for our financial reporting from the ICAI!
Athlete’s Day Out: Core Organising Committee of Celebrations of Excellence vs.
Management Council of Dr. Reddy's
Full set of clinical studies of our rituximab biosimilar successfully completed!
Launched in-house palbociclib (PRIMCYV®) to widen access to the trusted
high-quality breast cancer drug
A talk on 'Role of Medical Nutrition Therapy in management of Metabolic
Syndrome' at the 54th Annual Conference of Nutrition Society of India!
Grand Finale of Dr. Reddy's Digital Health Hackathon 2023!
Wall murals to outline the drug lifecycle at our corporate office in Hyderabad!
Kicking off National Road Safety Week 2023 in India!
Team Colombia earns ‘Great Place to Work’ Certification!
Our Water Ambassador Programme
Our in-house music band performs at live rock concert for Celebrations of
Excellence 2023!
Athlete’s Day Out - Marathon for Celebrations of Excellence 2023!
Launching the 2023 desk calendar curated by Team API!
Happy New Year! And a look at the year gone by!
Our Engineering Team of our formulations manufacturing plant wins five kaizen
awards!
Yet another ‘Product of the Year’ win for Celevida!
Christmas Celebrations by our global teams!
Graduation ceremony of the Young Leaders Program (YLP)!
Recognised as the winner in UiPath’s ‘Excellence in Other Industry-specific
Process Automation’
Athlete’s day out – Sports events of the Celebrations of Excellence 2023
Energy Ambassador Programme
Our nutraceutical team at PENSA 2022!
Aurigene Discovery Technologies is now Aurigene Oncology Limited!
Team Europe organised a zero-waste potluck!
Team North America at the Midyear Clinical Meeting and Exhibition of ASHP 2022!
Cultural Events of Celebrations of Excellence 2023!
Dr. Reddy's Foundation recognised by the President of India for GROW for Persons
with Disabilities!







LATEST NEWS


U.S. FDA ISSUES INSPECTION REPORT WITH VAI TO DR. REDDY’S PLANT


READ ALL NEWS


DR REDDY’S BACHUPALLY UNIT GETS USFDA EIR




LONG-TERM VISION OF INTERIM BUDGET HAILED (QUOTES OUR CHAIRMAN SATISH REDDY ON
THE UNION BUDGET OF INDIA 2024)




SUMMARY OF INDUSTRY LEADERS, ECONOMISTS’ FIRST VIEWS ON INTERIM BUDGET




OUR CEO, EREZ ISRAELI, ON OUR Q3 FY'24 PERFORMANCE




DR. REDDY’S NET RISES 11% ON STRONG US, EU SALES




OUR CFO, PARAG AGARWAL, ON OUR Q3 FY'24 PERFORMANCE




DR. REDDY’S PROFIT RISES 11% TO RS. 1379 CR IN Q3




DR REDDY’S SHARES HIT 52-WEEK HIGH ON STRONG Q3 RESULTS




OUR CEO, EREZ ISRAELI, ON OUR Q3 FY'24 PERFORMANCE



Back to Top

This website uses cookies to help us give you the best experience when you
visit. By using this website you consent to our use of cookies. For more
information please review our cookie policy. Cookie Policy

Accept
HOME

About Us

Building A Sustainable Future

#WeAreDrReddys

Latest News

WHO WE ARE

Purpose

Promises

Principles

Values

Leadership

Our Founder

Our Journey

OUR BUSINESSES

Our Businesses

Our Capabilities

Stories

Jobs

Contact Us

SUSTAINABILITY

Milestones

Our ESG Goals

Reports and Disclosures

Community Initiatives

Employee Volunteering

LIFE AT DR. REDDY'S

Our Culture

ASPIRE framework

Our People

Capability Building Programmes

Work With Us


INVESTORS

MEDIA

BUSINESS PARTNERS

JOB SEEKERS

CONTACT US

Terms Of Use

Privacy

Accessibility

Cookie Policy

Caution Notice - "Recruitment Fraud"

Privacy Notice for Job Applicants and Prospects


© 2024 Dr. Reddy’s Laboratories Ltd. All rights reserved.